Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs

Cocrystals can be used as an alternative approach based on crystal engineering to enhance specific physicochemical and biopharmaceutical properties of active pharmaceutical ingredients (APIs) when the approaches to salt or polymorph formation do not meet the expected targets. In this article, an ove...

Full description

Saved in:
Bibliographic Details
Main Authors: Anna Karagianni (Author), Maria Malamatari (Author), Kyriakos Kachrimanis (Author)
Format: Book
Published: MDPI AG, 2018-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_8aee6cd0549c4ab3bb8e58fe91ef3e4e
042 |a dc 
100 1 0 |a Anna Karagianni  |e author 
700 1 0 |a Maria Malamatari  |e author 
700 1 0 |a Kyriakos Kachrimanis  |e author 
245 0 0 |a Pharmaceutical Cocrystals: New Solid Phase Modification Approaches for the Formulation of APIs 
260 |b MDPI AG,   |c 2018-01-01T00:00:00Z. 
500 |a 1999-4923 
500 |a 10.3390/pharmaceutics10010018 
520 |a Cocrystals can be used as an alternative approach based on crystal engineering to enhance specific physicochemical and biopharmaceutical properties of active pharmaceutical ingredients (APIs) when the approaches to salt or polymorph formation do not meet the expected targets. In this article, an overview of pharmaceutical cocrystals will be presented, with an emphasis on the intermolecular interactions in cocrystals and the methods for their preparation. Furthermore, cocrystals of direct pharmaceutical interest, along with their in vitro properties and available in vivo data and characterization techniques are discussed, highlighting the potential of cocrystals as an attractive route for drug development. 
546 |a EN 
690 |a cocrystals 
690 |a coformers 
690 |a solid state properties 
690 |a poorly soluble APIs 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceutics, Vol 10, Iss 1, p 18 (2018) 
787 0 |n http://www.mdpi.com/1999-4923/10/1/18 
787 0 |n https://doaj.org/toc/1999-4923 
856 4 1 |u https://doaj.org/article/8aee6cd0549c4ab3bb8e58fe91ef3e4e  |z Connect to this object online.